The Powerhouse for Anti-infectives

Committed to making the difference

Read more

AiCuris is a pharmaceutical company specializing in the discovery, research and development of novel, resistance‐breaking antiviral and antibacterial agents for the treatment of serious and potentially life-threatening infectious diseases. Founded in 2006 as a spin‐out from Bayer Infection Research, AiCuris today manages an innovative pipeline of anti-infective agents with a team of internationally recognized scientists in Research and Development. We are one of the few European biotech companies which has brought a drug with “blockbuster” potential to the market (Prevymis® 2017/18).

Latest News


36th international conference on antiviral research (ICAR) 2023, March 13-17 in Lyon, France

AiCuris Anti-infective Cure AG will participate at ICAR 2023 conference. Visit our poster to discuss new ideas around: “Bridging the gap from fundamental virology to new antivirals”

Read more


Bio Europe Spring 2023, March 20-22 in Basel, Switzerland

AiCuris will participate at Bio Europe Spring 2023 conference. Meet us in Basel at Bio Europe Spring

Read more


AiCuris’ Licensing Partner MSD Demonstrates Efficacy in Phase 3 Study with PREVYMIS® for Prevention of Cytomegalovirus Disease in Adults After Kidney Transplantation

In late breaking presentation at IDweek MSD reported positive findings from a phase 3 clinical trial that met the primary endpoint.

Read more


AiCuris´ AiCubator calls for innovative proposals to propel anti-infective drug development in the third round

AiCuris´ innovation accelerator AiCubator calls for innovative proposals to propel anti-infective drug development in the third round.

Read more


AiCuris nominates team of researchers from the Universitätsklinikum Erlangen as one of the winners of AiCubator Resident Status

AiCuris´s corporate innovation accelerator AiCubator has been strengthened by a novel collaboration with researchers from the Universitätsklinikum Erlangen.

Read more


AiCuris appoints experienced business leader Dr. Sabrina Kuttruff-Coqui as Chief Financial Officer

“It is my pleasure to welcome Dr. Sabrina Kuttruff-Coqui as our new CFO”, said Dr. Stefan Oschmann, Chairman of the Board of AiCuris.

Read more

Research & Development

Our innovative Pipeline

Innovative therapies demand extraordinary means. With an international team of renowned scientists, proven competence in clinical development, and a global network of experts and reliable partners, we differentiate our pipeline by using an indication-driven, technology-agnostic approach.

Read more

Partnering & Collaborations

Expanding our Portfolio

AiCuris is constantly evaluating strategic partnerships and collaboration opportunities with biotech or pharmaceutical companies. In addition, we are always interested in new collaborations with innovative, science-driven organizations and academic institutions to develop the next resistance-breaking antibiotic or anti-infective.

Read more

If you or your company are interested in partnering with AiCuris, please contact us.